EP2056779A2 - Utilisation d'une composition de traitement de la peau en cas d'irradiation x - Google Patents

Utilisation d'une composition de traitement de la peau en cas d'irradiation x

Info

Publication number
EP2056779A2
EP2056779A2 EP07819967A EP07819967A EP2056779A2 EP 2056779 A2 EP2056779 A2 EP 2056779A2 EP 07819967 A EP07819967 A EP 07819967A EP 07819967 A EP07819967 A EP 07819967A EP 2056779 A2 EP2056779 A2 EP 2056779A2
Authority
EP
European Patent Office
Prior art keywords
composition
extract
weight
phospholipids
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07819967A
Other languages
German (de)
English (en)
Inventor
Karin Golz-Berner
Leonhard Zastrow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coty Germany GmbH
Original Assignee
Coty Prestige Lancaster Group GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coty Prestige Lancaster Group GmbH filed Critical Coty Prestige Lancaster Group GmbH
Publication of EP2056779A2 publication Critical patent/EP2056779A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/22—Peroxides; Oxygen; Ozone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
    • A61K8/70—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine containing perfluoro groups, e.g. perfluoroethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/81—Preparation or application process involves irradiation

Definitions

  • the invention relates to the use of a composition for the preparation of a dermatological agent for the prophylactic or therapeutic treatment of the skin before, during and / or after a therapy with X-rays, in particular in the case of previous tumor removal.
  • EP 91313 describes the mixing of perfluorocarbons with therapeutic agents, such as indomethacin, chloramphenicol, etc.
  • US Pat. No. 4,569,784 describes a gel with gas transport properties in the case of skin irritations or wounds consisting of fluorocarbon, emulsifier and water.
  • EP 0 647 131 B1 discloses a dermatological composition comprising asymmetric lamellar aggregates of phospholipids with 30 to 99% phosphatidylcholine and oxygen-charged fluorocarbons or fluorocarbon mixtures. The aggregates used in it are able to penetrate deeply into the skin and supply the skin with oxygen from the outside. Oxygen delivery to underserved adipose tissue as well as arteriosclerosis-related deficiency supplies is mentioned as the direction of use.
  • antioxidants or free radical scavengers in preparations for the skin.
  • the object of the invention is to improve the restoration of skin functions after therapeutically employed X-ray irradiation and to provide a dermatological agent therefor.
  • a composition is used for the preparation of a dermatological agent for the prophylactic or therapeutic treatment of skin during X-ray therapy, the composition comprising a) oxygen-carrying asymmetric lamellar aggregates comprising phospholipids having a phosphatidylcholine content of 30 to 99% by weight and fluorocarbons, b ) one or more water-soluble antioxidants selected from the group consisting of shell extract of white grapes; Plant extracts of the family Labiatae; Peel extract of white grapefruit; green tea extract; green coffee extract; a product obtained by extraction of the bark of Quebracho blanco and subsequent enzymatic hydrolysis and by addition of an extract of silkworms and in admixture with a gel and phospholipids; and mixtures thereof; wherein the composition has a Radical Protective Factor (RPF) of at least 4000 -10 14 radicals / mg.
  • RPF Radical Protective Factor
  • the treatment of the skin "with" a therapy with X-rays means that the treatment is carried out before the irradiation, during the irradiation, i.e. between the individual sessions, and / or after the irradiation.
  • compositions of oxygen-carrying asymmetric lamellar aggregates and certain antioxidants provided that this composition has a radical protection factor in the ready-to-use formulation of greater than 4000 * 10 14 radicals / mg, achieves significant improvements in use on X-ray damaged skin In particular, the elasticity of the skin can be significantly improved and the skin moisture can reach at least the normal state again.
  • the composition or the dermatological agent are normally used as a cream and exceed in their effects the previously used powder by far. It has also been found that, despite high levels of aggregates and certain antioxidants, stable formulations of aesthetic appeal can be made.
  • the dermatological composition further contains certain excipients and carriers, such as are commonly used in such preparations, for example water, preservatives, dyes, thickeners, alcohols, polyols, esters, electrolytes, gelling agents, polar and nonpolar oils, polyols. mers, copolymers, emulsifiers, stabilizers and emollients.
  • excipients and carriers such as are commonly used in such preparations, for example water, preservatives, dyes, thickeners, alcohols, polyols, esters, electrolytes, gelling agents, polar and nonpolar oils, polyols. mers, copolymers, emulsifiers, stabilizers and emollients.
  • Creatinine biotin, isoflavones or isoflavonoids. Also
  • Vitamin A and derivatives thereof carotenoids and carotenes such.
  • B ⁇ -carotene, ⁇ -carotene, uric acid and derivatives thereof, ⁇ -
  • a particularly preferred water-soluble antioxidant is a product obtained by extraction of the bark of Quebracho blanco and subsequent enzymatic hydrolysis containing at least 90% proanthocyanidin oligomers.
  • This product also contains an extract of silkworms containing the peptide cecropins, amino acids and a vitamin mixture. Both extracts are mixed with a gel and together with phospholipids. It is referred to in the examples as RPF complex I.
  • antioxidants are plant extracts of the Labiatae family, which include rosemary, oregano, sage and melissa. Particularly preferred are rosemary and oregano, such as rosmarinic acid-containing extracts or extract mixtures, e.g. the product Origanox®.
  • the antioxidants are preferably in the range of 0.5 to 5% by weight, in particular 2 to 3% by weight, based on the weight of the total composition.
  • the antioxidants used in the invention have a radical protection factor of greater than 4000 radicals per mg of the substance.
  • Radical Protection Factor determines the activity of free radical binding by an antioxidant towards a test substance.
  • This test substance consists of a highly reactive, semi-stable radical that reacts with all known antioxidants.
  • the measurement of the RPF is made by measuring the signal amplitude of the test radical by electron spin resonance (ESR / EPR) before and after mixing with an antioxidant and calculating the RPF therefrom.
  • the result of the test radical reduction RC x RF is normalized to the amount of product input PI (mg / ml).
  • the radical protection factor is calculated according to the following equation _ "" RC [radicals / ml] xRF KF b -
  • Preferred ranges for the RPF of the compositions of the present invention are 4000-8000 rad / mg, especially 5000-7000 rad / mg.
  • oils used for the invention may be conventional cosmetic oils, such as a mineral oil; hydrogenated polyisobutene, synthetic or derived from natural products squalane, cosmetic esters or ethers, which may be branched or unbranched, saturated or unsaturated; vegetable oils; or mixtures of two or more thereof.
  • oils are, for example, silicone oils and vegetable oils, such as calendula oil, jojoba oil, avocado oil, macadamia nut oil, borage oil, coconut oil, corn oil, cotton seed oil, olive oil, palm kernel oil, rapeseed oil, safflower oil, sesame seed oil, soybean oil, sunflower seed oil, wheat germ oil, grapeseed oil, kuku nut oil, thistle oil and mixtures thereof.
  • Particularly preferred is borage oil.
  • Preferred silicone oils are cyclic silicone oils such as cyclopentasilxoans, cyclotetrasilxoans and cyclohexasilxoans.
  • Polyols are also possible constituents of the dermatological agent according to the invention. These are, for example, propylene glycol, dipropylene glycol, ethylene glycol, isoprene glycol, glycerol, butylene glycol, sorbitol and mixtures thereof.
  • the dermatological composition of the present invention may also contain conventional humectants, such as glycerol, butylene glycol, propylene glycol, and mixtures thereof.
  • the dermatological agent of the invention may be in the form of a gel.
  • suitable gelling agents include carbomer, xanthan gum, carrageenan, gum acacia, guar gum, agar-agar, alginates and tyloses, carboxymethyl cellulose, hydroxyethyl cellulose, quaternized cellulose, quaternized guar, certain polyacrylates, polyvinyl alcohol, polyvinylpyrrolidone, montmorillonite.
  • the gelling agent is carbomer.
  • the asymmetric lamellar aggregates used in the invention have a three-layer structure. They carry in their core hydrophobic fluorocarbons, which are capable of transporting oxygen. Their surface chemical stabilization is primarily by a monolayer with inverse arrangement and secondarily by a subsequent construction of bilayer layers. According to the invention, the asymmetric lamellar aggregates therefore always have a three-layered structure, in contrast to the two-layered known vesicles. Because of the peculiarity of their structural arrangement, these are referred to as asymmetric lamellar aggregates.
  • the proportion of asymmetric lamellar aggregates is preferably in the range of 8 to 30% by weight, in particular 10 to 25% by weight.
  • the proportion of perfluorocarbon, preferably perfluorodecalin, within the aggregates is 10 to 45% by weight, preferably 20 to 40% by weight, based on the total weight of the aggregates.
  • composition according to the invention or the dermatological agent according to the invention is a cream.
  • the dermatological agent may also be present as a lotion or ointment.
  • the combination of oxygen-carrying aggregates and certain antioxidants has a significantly higher effect than the individual components. For example, it was found in the comparative experiment that an improvement in skin moisture and skin elasticity occurs to an unexpected degree.
  • the present invention also relates to a method for the prophylactic or therapeutic treatment of the skin of a subject during X-ray therapy, which comprises applying a dermatological agent to the X-ray exposed skin areas prior to the start of the treatment and after the repeated treatments comprising a composition comprising a) oxygen carrying asymmetric lamellar aggregates comprising phospholipids with a Phosphatidylcholine content of 30 to 99% by weight and fluorocarbons, b) one or more water-soluble antioxidants selected from the group consisting of plant extracts of the family Labiatae; Peel extract of white grapes; Shell extract of white grapefruit; green tea extract; green coffee extract; a product obtained by extraction of the bark of Quebracho blanco and subsequent enzymatic hydrolysis and addition of an extract of silkworms and in admixture with a gel and phospholipids; and mixtures thereof; wherein the agent has a radical protection factor (RPF) of at least 4000 -10 14 radicals / mg.
  • RPF radical protection factor
  • this complex of active ingredients was carried out by first preparing a gel base. To this was added gel powder, such as carbomer, in water, homogenized therein and then added e.g. neutralized with triethanolamine. Thereafter, an addition of ethanol and glycerol for ease of incorporation, wherein the corresponding mixture was stirred well.
  • gel powder such as carbomer
  • Example 1 The preparation of the composition of Example 1 is carried out by separately preparing the phases A and B at about 75 0 C with stirring. After combining phases A and B and homogenization for about 20 minutes, the mixture is cooled to about 40 ° C. Phase C is added with stirring, and at about 35 0 C, the phase D is added with stirring. This gives a stable over several months formulation with an aesthetic, slightly yellowish appearance.
  • the RPF is measured at 5800 rad / mg for the preferred composition.
  • composition was that of Example 1, but with 25% AOCS in Phase D.
  • the preparation and the appearance of the composition are the same as in Example 1.
  • the RPF is measured at 4900 rad / mg.
  • Verum group with a formulation according to example 1.
  • Placebo group with a formulation according to example 1 without phase D.
  • the SCORE score already shows a significant increase in the placebo group in the third week, while the verum group is still without any irritation.
  • the SCORE score increases significantly, but only very modestly for the verum group.
  • the Verum group showed about 40% less irritation score under radiation treatment than the placebo group.
  • the elasticity index for the verum group increased almost continuously over the course of 5 weeks from 2 to 26, while the increase for the placebo group was only from 2 to 8. This puts the verum group 19% better than the placebo group.
  • Cream A cream according to Example 2
  • Cream B Cream according to Example 2 without 2% RPF complex I and 3% green tea extract
  • Cream C cream according to Example 2 without 25% AOCS
  • the cream according to the invention thus shows significantly increased values which indicate a synergism.
  • Example 6 Body Cream IV
  • the composition of phases A, B and C corresponds to that of Example 1.
  • Green Tea Extract 0.5-4.8 3 Rosemary Officinalis Flower Extract 0.1-0.5 0.1
  • the RPF is measured at 5800 rad / mg for the preferred composition.
  • Example 7 Body Cream V
  • the composition is the same as in Example 6.
  • Oreganum Vulgar Leaf Extract (range 0.1-5%, preferably 1%) is included.
  • the RPF is measured at 6820 rad / mg for the preferred composition.
  • composition of phases A, B and C corresponds to that of Example 1.
  • Phase D region prefers RPF complex I * 0.5-5 2.8
  • the RPF is measured at 4200 rad / mg for the preferred composition.
  • phase A corresponds to that of example 1.
  • Phase D range is preferred
  • the RPF is measured at 4870 rad / mg for the preferred composition.
  • Example 10 Body Cream VIII The composition is similar to Example 9. Additionally included is Citrus Grandis (Grapefruit) Skin Extract (range 0.1-3, preferably 2.0). The RPF is measured at 5120 rad / mg for the preferred composition.
  • Example 11 Body Cream IX
  • composition corresponds to that of Example 1 without Green Tea Extract.
  • the RPF is measured at 5240 rad / mg.
  • composition corresponds to that of Example 6 without Green Tea Extract.
  • the RPF is measured at 5330 rad / mg.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Insects & Arthropods (AREA)
  • Dispersion Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne l'utilisation d'une composition pour préparer un agent dermatologique destiné au traitement de la peau en cas d'irradiation X répétée. La composition contient des agrégats lamellaires asymétriques porteurs d'oxygène à base de phospholipides et de fluorocarbones, ainsi que certains antioxydants solubles dans l'eau. Cette composition possède un coefficient de protection anti-radicaux au moins égal à 4000 1014 radicaux/mg.
EP07819967A 2006-08-24 2007-08-24 Utilisation d'une composition de traitement de la peau en cas d'irradiation x Withdrawn EP2056779A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006040450A DE102006040450B3 (de) 2006-08-24 2006-08-24 Verwendung einer Zusammensetzung für die Hautbehandlung nach Röntgenbestrahlung
PCT/EP2007/058832 WO2008023064A2 (fr) 2006-08-24 2007-08-24 Utilisation d'une composition de traitement de la peau en cas d'irradiation x

Publications (1)

Publication Number Publication Date
EP2056779A2 true EP2056779A2 (fr) 2009-05-13

Family

ID=38704833

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07819967A Withdrawn EP2056779A2 (fr) 2006-08-24 2007-08-24 Utilisation d'une composition de traitement de la peau en cas d'irradiation x

Country Status (6)

Country Link
US (1) US20100015242A1 (fr)
EP (1) EP2056779A2 (fr)
CN (1) CN101505714B (fr)
CA (1) CA2661506C (fr)
DE (1) DE102006040450B3 (fr)
WO (1) WO2008023064A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10039722B2 (en) 2008-10-14 2018-08-07 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
CN103520040B (zh) * 2013-10-12 2016-09-07 上海艳紫化工科技有限公司 玻璃苣保湿霜

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4569784A (en) * 1980-11-17 1986-02-11 Adamantech, Inc. Preparation of a gel having gas transporting capability
GR78151B (fr) * 1982-04-05 1984-09-26 Alcon Lab Inc
US5171755A (en) * 1988-04-29 1992-12-15 Hemagen/Pfc Emulsions of highly fluorinated organic compounds
DE4221268C2 (de) * 1992-06-26 1997-06-12 Lancaster Group Ag Verwendung eines Dermatikums zur Unterstützung des Sauerstofftransportes in der Haut
US5885564A (en) * 1993-08-13 1999-03-23 Lancaster Group Gmbh Functional oxygenated composition containing phospholipids and fluorocarbon
US6372234B1 (en) * 1997-05-27 2002-04-16 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
DE19860754B4 (de) * 1998-06-24 2004-10-28 Coty B.V. Kosmetische Zubereitung
US20040057974A1 (en) * 2002-08-06 2004-03-25 Naina Sachdev Antiwrinkle composition and age reversal complex
EP1730522A2 (fr) * 2004-03-29 2006-12-13 Howard Murad Procede pour traiter des etats dermatologiques d'un patient

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008023064A3 *

Also Published As

Publication number Publication date
WO2008023064A3 (fr) 2008-12-24
CN101505714A (zh) 2009-08-12
US20100015242A1 (en) 2010-01-21
CA2661506C (fr) 2017-02-21
CA2661506A1 (fr) 2008-02-28
CN101505714B (zh) 2013-03-13
DE102006040450B3 (de) 2008-04-24
WO2008023064A2 (fr) 2008-02-28

Similar Documents

Publication Publication Date Title
EP1513492B1 (fr) Microemulsions presentant une differentiabilite de phase binaire et de substance active, leur production et leur utilisation en particulier pour administrer de l'oxygene par voie topique
DE3686325T2 (de) Hydratierte lipidische lamellare phasen oder liposome mit retinoid oder deren analoga wie karotenoid enthaltende dermatologische, pharmazeutische oder kosmetische zusammensetzung.
EP2320754B1 (fr) Microémulsion
EP0847279B1 (fr) Compositions cosmetiques et/ou pharmaceutiques antiprurigineuses contenant un ou plusieurs anesthesiques locaux legers et un ou plusieurs astringents
DE3713493A1 (de) Kosmetisches oder pharmazeutisches mittel auf basis einer waessrigen dispersion von lipidkuegelchen
CN112891241A (zh) 一种靶向线粒体皮肤抗衰纳米组合物及其制备方法和应用
CN108186679B (zh) 一种祛痘组合物
KR20130134532A (ko) 피부 자극 완화 및 피부 장벽 회복을 위한 다중층 액정 베지클 및 이를 포함하는 화장료 조성물
KR102142311B1 (ko) 텐저레틴을 함유하는 피부 외용제 조성물
KR101325553B1 (ko) 아미노 레불리닉산을 배합시킨 액정 유화 베이스를포함하는 피부보호용 화장료 조성물
KR101418366B1 (ko) 봉독 및 프로폴리스를 함유하는 여드름 예방 또는 치료용 조성물
KR20120009147A (ko) 백화사설초 추출물을 함유하는 보습용 피부 외용제 조성물
DE102006040450B3 (de) Verwendung einer Zusammensetzung für die Hautbehandlung nach Röntgenbestrahlung
WO2016166091A1 (fr) Combinaison de substances naturelles contenant au moins un acide glycyrrhétinique et au moins un guggulstérone, et utilisation de cette dernière pour des applications cosmétiques
KR102013804B1 (ko) 유효성분을 함유한 큐보좀을 포함하는 화장료 조성물
EP2100592A1 (fr) Produit cosmétique doté d'un effet anti-vieillissement
WO2006117404A2 (fr) Utilisation de piegeurs de radicaux dans une preparation topique pour un traitement antipyretique
DE19618809C1 (de) Kosmetisches Mittel
KR101967576B1 (ko) 라멜라 리포좀으로 안정화된 백장미 추출물을 포함하는 항아토피, 항균 및 항염증용 화장료 조성물
US20120276174A1 (en) Therapeutic Treatment of Dermatologic Skin Disorders
EP2825265B1 (fr) Produit cosmétique pour peau mâture
CN112190576A (zh) 皮肤外用制剂的组合物、皮肤外用制剂及其制备方法
DE102015004672A1 (de) In Vesikeln formulierte Naturstoffkombination
DE102023103292A1 (de) Dispersion und Zubereitung zur topischen Anwendung
KR20240057003A (ko) 피부투과촉진 복합물을 포함하는 액정 겔 화장료 조성물

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090323

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

17Q First examination report despatched

Effective date: 20090817

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/02 20060101ALI20140117BHEP

Ipc: A61K 8/70 20060101ALI20140117BHEP

Ipc: A61Q 19/00 20060101ALI20140117BHEP

Ipc: A61K 8/55 20060101ALI20140117BHEP

Ipc: A61K 8/14 20060101AFI20140117BHEP

Ipc: A61K 9/06 20060101ALI20140117BHEP

Ipc: A61K 8/97 20060101ALI20140117BHEP

INTG Intention to grant announced

Effective date: 20140225

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: COTY GERMANY GMBH

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150303